DFine Announces First Patient Treated with STAR(TM) System in a Clinical Trial to Evaluate Targeted Radiofrequency Ablation Therapy for Spinal Tumors

SAN JOSE, Calif. & MAINZ, Germany--(BUSINESS WIRE)--DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced that the first patient - a 50-year old mother of three suffering from breast cancer - has been successfully treated using the Spinal Tumor Ablation with Radiofrequency (STAR)™ System in a prospective clinical trial to evaluate the safety and efficacy of targeted radiofrequency spinal tumor ablation and cement augmentation in patients with metastatic spinal tumors.